Spots Global Cancer Trial Database for A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer
Official Title: A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Nab-Paclitaxel and Gemcitabine With or Without Olaratumab in the Treatment of First-Line Metastatic Pancreatic Cancer
Study ID: NCT03086369
Conditions
Study Description
Brief Summary: The purpose of this study is to determine the safety and efficacy of nab-paclitaxel and gemcitabine with or without olaratumab in the treatment of first-line metastatic pancreatic cancer.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
TGen Clinical Research Services at Scottsdale Healthcare, Scottsdale, Arizona, United States
University of Arizona Cancer Center, Tucson, Arizona, United States
Highlands Oncology Group, Fayetteville, Arkansas, United States
Comprehensive Blood and Cancer Center, Bakersfield, California, United States
St Jude Medical Center, Fullerton, California, United States
TRIO - Translational Research in Oncology-US, Inc., Los Angeles, California, United States
UCLA Medical Center, Los Angeles, California, United States
Cancer Center of Santa Barbara with Sansum Clinic, Santa Barbara, California, United States
Central Coast Medical Oncology Corporation, Santa Maria, California, United States
Smilow Cancer Hospital at Yale-New Haven, New Haven, Connecticut, United States
Florida Cancer Specialists, Fort Myers, Florida, United States
Florida Cancer Specialists and Research Institute, Saint Petersburg, Florida, United States
H Lee Moffitt Cancer Center, Tampa, Florida, United States
Fort Wayne Oncology & Hematology, Fort Wayne, Indiana, United States
Cancer Center of Kansas, Wichita, Kansas, United States
Nebraska Methodist Hospital, Omaha, Nebraska, United States
Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States
Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
Roswell Park Cancer Institute, Buffalo, New York, United States
Monter Cancer Center, Lake Success, New York, United States
Thomas Jefferson University, Philadelphia, Pennsylvania, United States
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Medical University of South Carolina, Charleston, South Carolina, United States
Sanford Research/USD, Sioux Falls, South Dakota, United States
Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States
Sarah Cannon Research Institute SCRI, Nashville, Tennessee, United States
Tennessee Oncology PLLC, Nashville, Tennessee, United States
Vanderbilt University Medical Center, Nashville, Tennessee, United States
Univ of Texas Health Science Center at San Antonio, San Antonio, Texas, United States
University of Utah School of Medicine, Salt Lake City, Utah, United States
University of Wisconsin-Madison Hospital and Health Clinic, Madison, Wisconsin, United States
Charité Campus Virchow-Klinikum, Berlin, , Germany
Hospital Universitari Vall d'Hebron, Barcelona, , Spain
Contact Details
Name: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Affiliation: Eli Lilly and Company
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
